-
HORIZON PHARMA, INC. et al v. DR. REDDY'S LABORATORIES INC. et al DC CAFC
- 2:11-cv-02317
- D.N.J.
- Judge: Stanley R. Chesler
+2
- Filed: 04/21/2011
- Closed: 07/21/2017
- Latest Docket Entry: 03/10/2020
- PACER
4
Plaintiffs
2
Defendants
1
Accused
Product
2
Patents-in-Suit
2,284
Days in
Litigation
-
HORIZON PHARMA, INC. et al v. DR. REDDY'S LABORATORIES INC. et al DC CAFC
- 2:11-cv-02317
- D.N.J.
- Judge: Stanley R. Chesler
+2
- Filed: 04/21/2011
- Closed: 07/21/2017
- Latest Docket Entry: 03/10/2020
- PACER
Market Sector
Biotech and Pharma
Court
Referred Judges
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
5 |
The pharmaceutical composition of claim 1, wherein said acid inhibitor is a proton pump inhibitor selected from the group consisting of: omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole.
|
Valid
Entry 499 |
15 |
The pharmaceutical composition of any one of claims 1 or 7-14, wherein said acid inhibitor is a proton pump inhibitor.
|
Valid
Entry 499 |
52 |
The method of claim 51, wherein said pain or inflammation is due to either osteoarthritis or rheumatoid arthritis.
|
Valid
Entry 499 |
53 |
The pharmaceutical composition of any one of claims 5-11 wherein said unit dosage form is a multilayer tablet comprising a single core and one or more layers outside of said single core, wherein: i) said NSAID is present in said core; ii) said
view more
|
Valid
Entry 499 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A pharmaceutical composition in unit dosage form comprising therapeutically effective amounts of: (a) esomeprazole, wherein at least a portion of said esomeprazole is not surrounded by an enteric coating; and (b) naproxen surrounded by a coating that
view more
|
Valid (103 and 112)
Entry 499 |
2 |
The pharmaceutical composition of claim 1, wherein naproxen is present in said unit dosage form in an amount of 200-600 mg.
|
Valid (103 and 112)
Entry 499 |
3 |
The pharmaceutical composition of claim 1, wherein esomeprazole is present in said unit dosage form in an amount of from 5 to 100 mg.
|
Valid (103 and 112)
Entry 499 |
4 |
The pharmaceutical composition of claim 1, wherein naproxen is present in said unit dosage form in an amount of between 200-600 mg and esomeprazole in an amount of from 5 to 100 mg per unit dosage form.
|
Valid (103 and 112)
Entry 499 |
-
Infringement
Dr. Reddy's Lab., Inc.
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic 375 mg, 500 mg of naproxen and 20.71 mg esomeprazole magnesium naproxen delayedrelease tabletsGeneric naproxen and esomeprazole magnesium delayed-release tablets containing 375 mg of naproxen and 20.71 mg esomeprazole magnesiumGeneric naproxen and esomeprazole magnesium delayed-release tablets containing 500 mg of naproxen and 20.71 mg esomeprazole magnesiumNaproxen and esomeprazole magnesium product | US 6,926,907 B2 |
1, 5, 9, 10, 11, 12, 13, 14, 15, 16, 17, 21, 22, 23, 24, 28, 29, 32, 33, 34, 35, 37, 41, 42, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55
|
Infringement
Entry 381Entry 499 |
Esomeprazole Magnesium Delayed-Release TabletsGeneric 375 mg, 500 mg of naproxen and 20.71 mg esomeprazole magnesium naproxen delayedrelease tablets | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
Entry 499
|
Dr. Reddy's Laboratories Ltd.
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic 375 mg, 500 mg of naproxen and 20.71 mg esomeprazole magnesium naproxen delayedrelease tabletsGeneric naproxen and esomeprazole magnesium delayed-release tablets containing 375 mg of naproxen and 20.71 mg esomeprazole magnesiumGeneric naproxen and esomeprazole magnesium delayed-release tablets containing 500 mg of naproxen and 20.71 mg esomeprazole magnesiumNaproxen and esomeprazole magnesium product | US 6,926,907 B2 |
1, 5, 9, 10, 11, 12, 13, 14, 15, 16, 17, 21, 22, 23, 24, 28, 29, 32, 33, 34, 35, 37, 41, 42, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55
|
Infringement
Entry 381Entry 499 |
Esomeprazole Magnesium Delayed-Release TabletsGeneric 375 mg, 500 mg of naproxen and 20.71 mg esomeprazole magnesium naproxen delayedrelease tablets | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
Entry 499
|
Mylan Incorporated
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Esomeprazole Magnesium Delayed-Release Tablets | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
|
Mylan Laboratories Limited
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Esomeprazole Magnesium Delayed-Release Tablets | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
|
Mylan Pharmaceuticals Incorporated
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Esomeprazole Magnesium Delayed-Release Tablets | US 8,557,285 B2 |
1, 2, 3, 4
|
Infringement
|